NCT06581081View on ClinicalTrials.gov

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

NARecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2029

Conditions
Relapsed Adult ALLB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Interventions
BIOLOGICAL

Senl_B19 autologous CAR-T (S1904) treatment

Subjects enrolled in this study will first receive Senl\_B19 autologous CAR-T (S1904) treatment.

Trial Locations (1)

100044

RECRUITING

Peking University People'S Hospital, Beijing

All Listed Sponsors
collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

Peking University People's Hospital

OTHER